Heparin Increases HLA-G Levels in Primary Antiphospholipid Syndrome

Table 1

Demographic, anthropometric, clinical, and laboratory features of the 44 PAPS patients and 43 healthy controls that provided samples for the measurement of HLA-G levels.

	PAPS; 𝑛=44	Controls; 𝑛=43	𝑃
Age, years	42.47 (12.0)	39.83 (11.2)	0.29
White race, %	90.9	84.2	0.42
Arterial events, %	59.1	NA	—
Venous events, %	59.1	NA	—
Obstetric events, %	38.6	NA	—
Thrombocytopenia, %	18.2	NA	—
Livedo reticularis, %	34.1	NA
Stroke, %	43.2	NA	—
Sneddon’s syndrome, %	24.5	NA	—
Pulmonary thromboembolism, %	27.3	NA	—
Deep venous thrombosis, %	54.5	NA	—
Angina, %	9.1	NA
Disease duration, months	97.9 (70.3)	NA	—
Previous history of smoking, %	38.6	NA	—
Current smoking, %	11.4	NA	—
Heparin use, %	66	NA	—
Current chloroquine use, %	40.9	NA	—
HLA-G, ng/mL^#	3.35 (0–22.9)	1.1 (0–14)	0.017

NA: not applicable.
Data expressed as a mean (standard deviation), ^#median (minimum-maximum), or a percentage.